• Recognized as "Corporate Attorney of the Year" by the Los Angeles Business Journal in 2019
• Recognized in the Legal 500

Select Matters

Mergers and Acquisitions

• Represented DTx Pharma, a biotech company, in its sale to Novartis
• Represented XinThera, a biotech company, in its sale to Gilead
• Represented Amphastar Pharmaceuticals in its acquisition of Eli Lilly’s low blood sugar drug BAQSIMI
• Represented Caption Health, an AI healthcare leader that creates clinical applications to aid in early disease detection, in its sale to GE HealthCare
• Represented Inscopix, a company focused on high performance scientific instruments and analytical and diagnostic solutions, in its sale to Bruker
• Represented Obsidio, a medical device company, in its sale to Boston Scientific
• Represented Novosteo, a clinical-stage biopharmaceutical company, in its sale to Cortexyme
• Represented PillPack, an online pharmacy, in its sale to Amazon*
• Represented Repligen, a life sciences company focused on bioprocessing technology leadership, in numerous acquisitions including its acquisitions of C Technologies, Spectrum, ArteSYN, Non-Metallic Solutions, Engineered Molding Technology, and BioFlex Solutions*
• Represented Olo, a company that develops digital ordering and delivery programs for restaurants, in its acquisition of Wisely*
• Represented BlueRock Therapeutics, a biotechnology company focusing on developing stem cell therapies, in its sale to Bayer*
• Represented TripleLift, an adtech company, in its sale to Vista*
• Represented AppNexus, an adtech company, in its acquisition of Open AdStream, YieldEx, MediaGlu, and Realmedia Latin America and in its sale to AT&T*
• Represented Virustream, a cloud management firm, in its sale to EMC*
• Represented Promedior, a clinical-stage immunotherapy company, in its grant to Bristol-Myers Squibb of an exclusive right to acquire Promedior and its ultimate sale to Roche*
• Represented EverTrue, a company that develops advancement software, in its combination with ThankView and investment by Rubicon Technology Partners*
• Represented Exosome, a company that develops and sells diagnostics that test for exosomes, in its sale to Bio-Techne*
• Represented Aporeto, a machine identity-based microsegmentation company, in its sale to Palo Alto Networks*
• OVH, a cloud service provider, in its acquisition of the vCloud Air business from VMware*
• Represented Teva Pharmaceuticals, a pharmaceutical company, in its sale of its animal health business to Bayer Healthcare and its sale of four targeted oncology development programs to Ignyta*
• Represented Interactions, a technology company, in its acquisition of the AT&T Watson technology program*
• Represented Bomgar, a provider of enterprise remote support solutions, in TA Associates' majority investment in Bomgar*
• Represented Numara Software, a provider of integrated IT management solutions, in its sale to BMC Software*
• Represented Digital Lumens, a developer of industrial IoT solutions, in its sale to Osram*

Financings and Joint Ventures

• Represented BridgeBio, a biotechnology company that focuses on identifying and advancing transformative medicines for genetic diseases, in its joint venture with Maze Therapeutics and in its $299 million financing*
• Represented Century Therapeutics, a biotechnology company focusing on developing stem cell therapies for cancer, in its joint venture with Bayer*
• Represented Versant Ventures, a venture capital firm focused on the healthcare sector, in its formation of BlueRock Therapeutics and joint venture with Bayer*
• Represented CRISPR Therapeutics, a biotechnology company, in its formation of Casebia Therapeutics and joint venture with Bayer*
• Represented Arvinas, a biotechnology company, in its joint venture with Bayer (Oerth Bio) focused on developing new agricultural products*
• Represented Ginkgo Bioworks, a biotechnology company, in its joint venture with Bayer (Joyn Bio) focused on the plant microbiome*
• Represented MyoKardia, a company developing precision therapies for genetic heart disease, in its $46 million financing*
• Represented Phreesia, a healthcare point-of-service platform, in its $30 million financing led by LLR Partners*
• Represented Global Blood Therapeutics, a biopharmaceutical company developing therapeutics for the treatment of severe blood disorders, in its $48 million financing*

Initial Public Offerings

• Represented BridgeBio, a biotechnology company that focuses on identifying and advancing transformative medicines for genetic diseases, in its initial public offering*
• Represented MyoKardia, a company developing precision therapies for genetic heart disease, in its initial public offering*

* Denotes experience at another firm prior to joining Wilson Sonsini in 2022.

Select Publications

• Co-author, “How to Navigate the Decision of Exercising Drag-Along Rights During an M&A Process," Deal Lawyers, September-October 2022